Abstract
Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event.
Lingua originale | Inglese |
---|---|
pagine (da-a) | 257-257-62.e3 |
Rivista | Journal of the American Academy of Dermatology |
Volume | 70 |
DOI | |
Stato di pubblicazione | Pubblicato - 2014 |
Keywords
- 75% improvement in the Psoriasis Area Severity Index score
- Adult
- Analysis of Variance
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Humanized
- Cohort Studies
- Confidence Intervals
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Follow-Up Studies
- Humans
- Immunoglobulin G
- Italy
- Male
- Middle Aged
- Multivariate Analysis
- PASI
- PASI 75
- Predictive Value of Tests
- Proportional Hazards Models
- Psoriasis
- Psoriasis Area Severity Index
- Receptors, Tumor Necrosis Factor
- Registries
- Retrospective Studies
- Risk Assessment
- Severity of Illness Index
- TNF
- Treatment Outcome
- Tumor Necrosis Factor-alpha
- Young Adult
- biologics
- efficacy
- primary inefficacy
- psoriasis
- secondary loss of efficacy
- switching
- tumor necrosis factor
- tumor necrosis factor-alfa inhibitors